What Are the Advertising Regulations in the UAE for Medical Products and More?
Answer:
Advertising regulations in the UAE are subject to severe standards, especially when it comes to medical products, the pharmacy profession, and pharmaceutical institutions. Federal Law No. 8/2019, also known as the “Law on Medical Products, Profession of Pharmacy, and Pharmaceutical Institutions,” lays down comprehensive guidelines for advertising in this sector.
These regulations aim to safeguard public health, ensure the proper practice of pharmacy, and maintain the integrity of the pharmaceutical industry. This article explores the key aspects of advertising regulations under Federal Law No. 8/2019.
Purpose of Advertising Regulations:
The primary objective of advertising regulations in the UAE, as specified in Article 3 of Federal Law No. 8/2019, is to prevent misleading or false information from reaching consumers regarding medical products, pharmaceutical services, and the pharmacy profession. These regulations seek to maintain transparency, promote ethical practices, and protect the well-being of the public.
Advertising Prohibition and Permissible Cases:
Under this article 39 establishes a clear prohibition on advertising prescription medicinal products to the general public through any means. However, it does allow for specific cases with the approval of the Ministry. Permissible cases include:
Announcing, advertising, or promoting a medical product in magazines or scientific resources intended for healthcare practitioners.
Announcing, advertising, or promoting to the public any non-prescription medical product or healthcare product that has obtained Marketing Authorization. This article underlines the importance of distinguishing between prescription and non-prescription products in advertising campaigns.
Marketing Authorization Holder:
The Marketing Authorization Holder is responsible for ensuring that all promotional advertisements for medical products fulfil the conditions and rules approved by the Ministry. Licensees, including those involved in manufacturing, marketing, or distributing medical products, are prohibited from engaging in activities involving falsification, fraud, theft, or plagiarism of published studies and research that could affect the legal rights of the research owners. as specified in Article 40 and 41 of the federal law.s
Prohibitions on Trading and Sale:
Article 42 establishes strict prohibitions on the trading and sale of falsified, defective, or expired medical products. Free advertising samples of medical products may not be sold, and any such samples must be clearly labelled with the phrase “Free medical sample not intended for sale” in both Arabic and English.
Free samples of medical products may only be provided to healthcare practitioners authorized to prescribe these products to patients as per Article 43.
A detailed record of the distribution of these samples, especially for controlled products, must be maintained to ensure transparency and accountability in the distribution process.
Disciplinary Sanctions:
The licensing authority for Pharmaceutical Institutions and its officials can impose disciplinary sanctions for violations of the law. Sanctions include written notices, warnings, fines, temporary license suspension, and license cancellation. A register of sanctions will be maintained, and disciplinary committees can exchange information about violations.
Penalties under Federal Law No. 8/2019:
Violations of this law will result in disciplinary sanctions, which may include written notices, warnings, fines ranging from 1,000 to 1,000,000 dirhams, temporary suspension of licenses, and even license cancellations for Pharmaceutical Institutions and practitioners of the Pharmacy Profession.
Criminal penalties include imprisonment ranging from six months to five years and fines from 50,000 to 500,000 dirhams, depending on the offence. Additional penalties may include the closure of facilities, confiscation of materials, and the costs of destroying harmful materials. It’s important to note that the requirements of this law do not exempt individuals from obtaining other required licenses under other laws.
Grievance Procedure:
Article 113 of the law addresses the process of filing grievances against disciplinary sanctions. Individuals subject to disciplinary sanctions can file grievances with the Grievance Committee within 15 days of the decision. The grievance must be decided within 30 days.
In conclusion, these comprehensive regulations are designed to ensure that medical product advertising in the UAE is conducted responsibly, transparently, and in compliance with established standards, safeguarding the health and interests of the public.